MDP Stock Overview
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.62 |
| 52 Week High | CA$3.53 |
| 52 Week Low | CA$1.12 |
| Beta | 1.85 |
| 1 Month Change | 3.85% |
| 3 Month Change | -36.47% |
| 1 Year Change | 17.39% |
| 3 Year Change | -78.40% |
| 5 Year Change | -59.60% |
| Change since IPO | -78.40% |
Recent News & Updates
Recent updates
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Jan 06Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Oct 11Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky
Jan 19Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 22Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?
Dec 16Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 21Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Aug 04Medexus Pharmaceuticals Inc. (CVE:MDP): When Will It Breakeven?
May 04The Independent Director of Medexus Pharmaceuticals Inc. (CVE:MDP), Michael Mueller, Just Bought 34% More Shares
Feb 26Did Business Growth Power Medexus Pharmaceuticals' (CVE:MDP) Share Price Gain of 174%?
Feb 24Shareholder Returns
| MDP | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 5.2% | -1.8% | -0.6% |
| 1Y | 17.4% | 50.8% | 3.9% |
Return vs Industry: MDP underperformed the Canadian Pharmaceuticals industry which returned 50.8% over the past year.
Return vs Market: MDP exceeded the Canadian Market which returned 3.9% over the past year.
Price Volatility
| MDP volatility | |
|---|---|
| MDP Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 13.9% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: MDP's share price has been volatile over the past 3 months.
Volatility Over Time: MDP's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 98 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Medexus Pharmaceuticals Inc. Fundamentals Summary
| MDP fundamental statistics | |
|---|---|
| Market cap | CA$39.62m |
| Earnings (TTM) | CA$8.06m |
| Revenue (TTM) | CA$158.57m |
4.9x
P/E Ratio0.2x
P/S RatioIs MDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDP income statement (TTM) | |
|---|---|
| Revenue | US$115.73m |
| Cost of Revenue | US$48.91m |
| Gross Profit | US$66.81m |
| Other Expenses | US$60.93m |
| Earnings | US$5.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 57.73% |
| Net Profit Margin | 5.08% |
| Debt/Equity Ratio | 174.9% |
How did MDP perform over the long term?
See historical performance and comparison